SCHEMBL11312410

SCHEMBL11312410

Cc1ccc(C(=O)Oc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
PRSS1 P07477 1/20 0.61
ACR P10323 1/20 0.61
SRD5A2 P31213 1/20 0.59
HSD17B10 Q99714 2/20 0.55
KMT2A Q03164 7/20 0.54
MEN1 O00255 2/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
TDP1 Q9NUW8 2/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
LMNA P02545 1/20 0.53
PARP10 Q53GL7 1/20 0.53
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
GBA1 P04062 1/20 0.51
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25438849 1.00 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2PRSS1ACRSRD5A2
SCHEMBL29993193 0.95 HSD17B10 (0.64) ALDH1A1SMN1; SMN2PRSS1ACRSRD5A2
SCHEMBL2741098 0.92 PRSS1 (0.69) ALDH1A1SMN1; SMN2PRSS1ACRHSD17B10
SCHEMBL9663961 0.92 PRSS1 (0.69) ALDH1A1SMN1; SMN2PRSS1ACRHSD17B10
SCHEMBL8929987 0.92 PRSS1 (0.69) ALDH1A1SMN1; SMN2PRSS1ACRHSD17B10
SCHEMBL8930157 0.92 PRSS1 (0.69) ALDH1A1SMN1; SMN2PRSS1ACRHSD17B10
SCHEMBL1101878 0.92 PRSS1 (0.69) ALDH1A1SMN1; SMN2PRSS1ACRHSD17B10
SCHEMBL4597931 0.90 PARP10 (0.62) ALDH1A1PRSS1ACRSRD5A2HSD17B10
SCHEMBL376498 0.90 PARP10 (0.62) ALDH1A1PRSS1ACRSRD5A2HSD17B10
SCHEMBL7536846 0.90 PARP10 (0.62) ALDH1A1PRSS1ACRSRD5A2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017059942-A1 CHIRAL COMPOUNDS MERCK PATENT GMBH (DE) 2017-04-13 WO disclosed
WO-2017025167-A1 MATERIAL COMBINATION MERCK PATENT GMBH (DE) 2017-02-16 WO disclosed
WO-2014169985-A1 MESOGENIC COMPOUND, LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2014-10-23 WO disclosed
WO-2013156113-A1 LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2013-10-24 WO disclosed
US-8449953-B2 Chiral dopants, liquid crystal matrix and manufacturing method thereof and liquid crystal display INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2013-05-28 US disclosed
WO-2013034219-A1 LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2013-03-14 WO disclosed
US-20130063693-A1 CHIRAL DOPANTS, LIQUID CRYSTAL MATRIX AND MANUFACTURING METHOD THEREOF AND LIQUID CRYSTAL DISPLAY INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2013-03-14 US disclosed
US-7198827-B1 Nematic liquid crystal composition and liquid crystal display device using the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2007-04-03 US disclosed
US-4259383-A PEROXY COMPOUNDS STERLING DRUG INC. (US) 1981-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130063693-A1 CHIRAL DOPANTS, LIQUID CRYSTAL MATRIX AND MANUFACTURING METHOD THEREOF AND LIQUID CRYSTAL DISPLAY CNPY2, YBX3, CCR3 ALDH1A1 3647/4885SMN1; SMN2 2173/4885PRSS1 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.